Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

J. B. Chemicals & Pharmaceuticals Limited manufactures and markets pharmaceutical formulations, herbal remedies, and active pharmaceutical ingredients (API) in India and internationally. The company's API product portfolio includes diclofenac sodium, diethylamine, acid, and potassium; nifedipine, atenolol, and cilnidipine; and ciprofloxacin, cetirizine, and meclizine HCI. It also provides dosage forms, such as tablets, lozenges, injectables, gels, creams, ointments, liquid herbal syrups, cold rubs, eye drops, troches, and capsules; and soft-centered, powder, medicated, and herbal lozenges, as well as various pharmaceutical dosage forms. In addition, it offers a range of contrast media products, including x-ray, magnetic resonance imaging (MRI), and ultrasound scanners; and contract manufacturing services. The company provides its products in gastroenterology, anti-infectives, wound care, neonatology and pediatrics, gynaecology, dental, vitamins and minerals, hypertension, diabetes, nephrology, respiratory, pain-analgesic, dermatology, antivirals, lozenges, and contrast media and radio diagnostic therapeutic areas. J. B. Chemicals & Pharmaceuticals Limited was incorporated in 1976 and is headquartered in Mumbai, India.

Revenue projections:

Revenue projections for JBCHEPHARM
Revenue projections for JBCHEPHARM

JBCHEPHARM's revenue is forecasted to dip below last year's figures, raising concerns for investors who are typically wary of declining financial performance. Such drops can directly affect the company's bottom line, potentially leading to a decrease in overall profitability, making investors more cautious in their decisions.

Financial Ratios:

currentRatio 0.000000
forwardPE 34.128067
debtToEquity 1.075000
earningsGrowth 0.216000
revenueGrowth 0.105000
grossMargins 0.670510
operatingMargins 0.235240
trailingEps 47.410000
forwardEps 60.062000

With positive growth in both earnings and revenue, JBCHEPHARM is expected to grow its business. These indicators highlight a strong financial outlook, with the company on track for continued expansion and increasing profitability.
J. B. Chemicals & Pharmaceuticals Limited's positive gross and operating margins suggest that the company is operating profitably. These strong margins indicate effective cost management and revenue generation, contributing to a solid financial foundation.
JBCHEPHARM's forward EPS being higher than its trailing EPS indicates that the company is expected to achieve greater profitability this financial year. This suggests improving earnings and a stronger financial position compared to the previous year's performance.

Price projections:

Price projections for JBCHEPHARM
Price projections for JBCHEPHARM

Price projections for J. B. Chemicals & Pharmaceuticals Limited have been revised upward over time, signaling increasing optimism about the company's future. This steady increase reflects a positive outlook for J. B. Chemicals & Pharmaceuticals Limited's growth and market performance.

Insider Transactions:

Insider Transactions for JBCHEPHARM
Insider Transactions for JBCHEPHARM


JBCHEPHARM had 57 sell transactions, while the market price was at 1716.6921065481085 per share.There were 3 buy transactions of JBCHEPHARM stock, with market price at 1875.4333089192708 per share.The trend of more buys compared to sells around JBCHEPHARM's current price levels may signal investor optimism. This behavior suggests that the market is expecting a favorable outcome for the stock, leading to increased buying activity.

Recommendation changes over time:

Recommendations trend for JBCHEPHARM
Recommendations trend for JBCHEPHARM


A recent buy bias from analysts toward JBCHEPHARM may inspire confidence in investors, who could view the stock as a promising investment. This positive sentiment suggests that JBCHEPHARM might be an appealing option for those looking to grow their wealth through stock market investments.